GlassScriptPhysician profile
David Matthew Ziebarth
NPI 1265532097
$3,352.61
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $827 · 2020: $878 · 2021: $629 · 2022: $533 · 2023: $484.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $484.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $484.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $1,543.75 | 2019-2023 | Dyanavel Xr, Quillichew Er, Quillivant |
| Takeda Pharmaceuticals U.S.A., INC. | $293.80 | 2020-2022 | |
| Glaxosmithkline, LLC. | $265.39 | 2020-2023 | Bexsero |
| Pfizer INC. | $235.87 | 2019-2023 | |
| Arbor Pharmaceuticals, INC. | $185.73 | 2019-2020 | |
| Adlon Therapeutics L.P. | $180.87 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $164.88 | 2019-2023 | Gardasil 9, Vaxneuvance, Vaxelis |
| Ironshore Pharmaceuticals INC. | $148.32 | 2019-2023 | Jornay Pm |
| Neos Therapeutics, LP | $134.06 | 2019-2020 | |
| Shire North American Group INC | $66.55 | 2019 | |
| Kaleo, INC. | $53.24 | 2019-2020 | |
| Genentech USA, INC. | $43.81 | 2020-2022 | |
| Dermira, INC. | $36.34 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Ziebarth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.